United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
| Revenue (TTM) | $3.15B |
| Gross Profit (TTM) | $2.72B |
| EBITDA | $1.50B |
| Operating Margin | 42.20% |
| Return on Equity | 19.30% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $72.85 |
| Book Value | $149.97 |
| Price-to-Book | 3.33 |
| Price-to-Sales (TTM) | 7.25 |
| EV/Revenue | 5.78 |
| EV/EBITDA | 10.87 |
| Quarterly Earnings Growth (YoY) | 13.40% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $42.89M |
| Float | $39.21M |
| % Insiders | 2.00% |
| % Institutions | 100.04% |
Volatility is currently contracting
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics' patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD).“We are pleased with the Co.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTHR and any ticker you trade — then tracks every position and per-strategy win rate.
